Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Eli Lilly and Loxo Oncology have announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers.

Lilly to bag Loxo Oncology for $8 billion

The acquisition would be the largest and latest in a series of transactions Lilly has conducted to broaden its cancer treatment efforts with externally sourced opportunities for first-in-class and best-in-class therapies. Loxo Oncology is developing a pipeline of targeted medicines focused on cancers that are uniquely dependent on single gene abnormalities that can be detected by genomic testing. For patients with cancers that harbor these genomic alterations, a targeted medicine could have the potential to treat the cancer with dramatic effect.

Loxo Oncology has a promising portfolio of approved and investigational medicines, including

  • LOXO-292, a first-in-class oral RET inhibitor that has been granted Breakthrough Therapy designation by the FDA for three indications, with an initial potential launch in 2020. LOXO-292 targets cancers with alterations to the rearranged during transfection (RET) kinase. RET fusions and mutations occur across multiple tumor types, including certain lung and thyroid cancers as well as a subset of other cancers.
  • LOXO-305, an oral BTK inhibitor currently in Phase I/II. LOXO-305 targets cancers with alterations to the Bruton's tyrosine kinase (BTK), and is designed to address acquired resistance to currently available BTK inhibitors. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas.
  • Vitrakvi, a first-in-class oral TRK inhibitor developed and commercialized in collaboration with Bayer that was recently approved by the FDA. Vitrakvi is the first treatment that targets a specific genetic abnormality to receive a tumour-agnostic indication at the time of initial FDA approval.
  • LOXO-195, a follow-on TRK inhibitor also being studied by Loxo Oncology and Bayer for acquired resistance to TRK inhibition, with a potential launch in 2022.
  • "Using tailored medicines to target key tumour dependencies offers an increasingly robust approach to cancer treatment," said Daniel Skovronsky, Lilly's chief scientific officer and president of Lilly Research Laboratories. "Loxo Oncology's portfolio of RET, BTK and TRK inhibitors targeted specifically to patients with mutations or fusions in these genes, in combination with advanced diagnostics that allow us to know exactly which patients may benefit, creates new opportunities to improve the lives of people with advanced cancer."

    "We are gratified that Lilly has recognized our contributions to the field of precision medicine and are excited to see our pipeline benefit from the resources and global reach of the Lilly organization," said Josh Bilenker, CEO of Loxo Oncology. "Tumour genomic profiling is becoming standard-of-care, and it will be critical to continue innovating against new targets, while anticipating mechanisms of resistance to available therapies, so that patients with advanced cancer have the chance to live longer and better lives."

    "Lilly Oncology is committed to developing innovative, breakthrough medicines that will make a meaningful difference for people with cancer and help them live longer, healthier lives," said Anne White, president of Lilly Oncology. "The acquisition of Loxo Oncology represents an exciting and immediate opportunity to expand the breadth of our portfolio into precision medicines and target cancers that are caused by specific gene abnormalities. The ability to target tumor dependencies in these populations is a key part of our Lilly Oncology strategy. We look forward to continuing to advance the pioneering scientific innovation begun by Loxo Oncology."

    "We are excited to have reached this agreement with a team that shares our commitment to ensuring that emerging translational science reaches patients in need," said Jacob Van Naarden, chief operating officer of Loxo Oncology. "We are confident that the work we have started, which includes an FDA approved drug, and a pipeline spanning from Phase II to discovery, will continue to thrive in Lilly's hands."

    Read More

    Related tags

    Market News

    Related news

    GSK partners with Samsung Biologics to secure additional manufacturing capacity

    GSK partners with Samsung Biologics to secure additional manufacturing capacity

    26 May 2020

    The agreement will initially cover the commercial production of Benlysta (belimumab) with the intention to expand to additional specialty-care products in the future.

    Read more 
    Changes needed to prevent controversial pay-for-delay pharma deals

    Changes needed to prevent controversial pay-for-delay pharma deals

    26 May 2020

    Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.

    Read more 
    SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

    SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

    26 May 2020

    SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.

    Read more 
    AbCellera and Lilly seal multi-year antibody discovery collaboration

    AbCellera and Lilly seal multi-year antibody discovery collaboration

    25 May 2020

    AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.

    Read more 
    HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

    HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

    25 May 2020

    The invention could pave the way for treatments to cure Parkinson's and Alzheimer's disease.

    Read more 
    Can the industry really claim it's 'business as usual'?

    Can the industry really claim it's 'business as usual'?

    19 May 2020

    ChargePoint Technology's Chief Commercial Officer says "yes" it can.

    Read more 
    HKBU scientists develop technique to eliminate drug side effects

    HKBU scientists develop technique to eliminate drug side effects

    19 May 2020

    The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

    Read more 
    Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

    Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

    19 May 2020

    The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

    Read more 
    Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

    Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

    18 May 2020

    CDMO is contracted to produce multiple clinical batches from German facility

    Read more 
    Pharmapack expert recommends holistic approach to sustainability

    Pharmapack expert recommends holistic approach to sustainability

    18 May 2020

    Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

    Read more